Datapoint: FDA Approves Generic Restasis

The FDA on Feb. 2 approved Vitaris’ generic form of AbbVie’s Restasis to treat patients with keratoconjunctivitis sicca, also known as dry eye. Restasis is a top seller for AbbVie, generating $1.2 billion in sales in 2021. This is the drug’s first generic competitor. For the treatment of dry eye, Restasis holds covered or better status for 95% of all insured lives. 44% of covered lives have preferred access to Restasis without utilization management restrictions.

SOURCE: MMIT Analytics, as of 2/7/22

0

0

0 Comments

0

0

• Datapoint